Author Of 1 Presentation
P0483 - Prevalence of cancer in multiple sclerosis patients in Argentina: cross sectional study from RelevarEM (ID 1043)
- G. Luetic
- M. Menichini
- C. Vrech
- A. Pappolla
- J. Miguez
- L. Patrucco
- J. Correale
- M. Marrodan
- M. Gaitán
- M. Fiol
- L. Negrotto
- M. Ysrraelit
- E. Cristiano
- A. Carrá
- A. Chertcoff
- J. Steinberg
- A. Martinez
- C. Curbelo
- L. Cohen
- R. Alonso
- O. Garcea
- C. Pita
- B. Silva
- N. Deri
- M. Balbuena
- V. Tkachuk
- E. Carnero Contentti
- P. Lopez
- J. Pettinicchi
- A. Caride
- M. Burgos
- F. Leguizamon
- E. Knorre
- R. Piedrabuena
- A. Barboza
- S. Liwacki
- P. Nofal
- G. Volman
- A. Alves Pinheiro
- J. Hryb
- D. Tavolini
- P. Blaya
- L. Recchia
- C. Mainella
- E. Silva
- J. Blanche
- S. Tizio
- M. Saladino
- F. Caceres
- N. Fernandez Liguori
- L. Lazaro
- G. Zanga
- M. Parada Marcilla
- M. Fracaro
- F. Pagani Cassará
- G. Vazquez
- V. Sinay
- G. Sgrilli
- P. Divi
- M. Jacobo
- E. Reich
- L. Cabrera
- M. Coppola
- I. Martos
- M. Kohler
- E. Kohler
- J. Viglione
- G. Jose
- S. Bestoso
- R. Manzi
- J. Rojas
- M. Alonso Serena
- O. (relevarem)
Abstract
Background
Multiple Sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system of multifactorial origin. Studies about the prevalence of cancer in MS population are scarce and results are conflicting. Previous studies described a higher prevalence as well as an increased risk of cancer in MS patients while there are others that found no differences regarding general population.
Objectives
The aim of our study was to estimate the prevalence of cancer in a large sample of multiple sclerosis patients in Argentina.
Methods
the eligible study population and cohort selection included all patients with definite MS included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03375177) at 31 December 2019. History of current or past cancer diagnosis, was collected. Prevalence rates and 95% CI were calculated.
Results
We analyzed 2647 MS patients. 14 malignancies were identified. Overall prevalence of cancer was 0.53% (CI95% 0.02-0.08%). 78.6% were female, 85.8% relapsing remitting MS, median (IQR) disease duration: 10.5 (6-13) years; median (IQR) age at diagnosis: 42.5 (37-49); median (IQR) age at study date: 52.5, median (IQR); current EDSS: 2 (1.5-4.5); 42% patients were untreated and 58% under DMT (beta interferon 1a: 14.3%, 1b: 7.1%, glatiramer acetate: 7.1% and fingolimod: 28.6%). Most frequent malignancy was breast cancer (28.6%).
Conclusions
The prevalence of cancer in MS population identified in Argentina was 0.53% (CI 95% 0.02-0.08), being females more affected than males and breast cancer the most frequent one.